Allergic Rhinitis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of allergic rhinitis (AR) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of AR for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s AR forecast will answer the following questions:

• Of all people with AR, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with AR, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AR over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts nine AR patient populations, as follows:

• Total prevalent cases of AR.
• Total prevalent cases of persistent AR.
• Total prevalent cases of intermittent AR.
• Total prevalent cases of mild AR.
• Total prevalent cases of moderate to severe AR.
• Diagnosed prevalent cases of AR.
• Undiagnosed prevalent cases of AR.
• Diagnosed drug-treated prevalent cases of AR.
• Diagnosed non-drug-treated prevalent cases of AR.

Note: Coverage may vary by country.